Bulletin
Investor Alert

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Regeneron Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 31, 2023, 7:38 p.m.

REGN
/zigman2/quotes/203149337/composite

$

821.77

Change

+0.10 +0.01%

Volume

Volume 42,758

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Previous close

$ 811.50

$ 821.67

Change

+10.17 +1.25%

Day low

Day high

$810.95

$822.52

Open

52 week low

52 week high

$538.01

$835.00

Open

Insider Actions for Regeneron Pharmaceuticals Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/10/2023 Joseph J. LaRosa
EVP General Counsel and Secret 		1,006   Gift at $0 per share. 0
02/22/2023 P. Roy Vagelos
Director 		29,005   Derivative/Non-derivative trans. at $750.16 per share. 21,758,390
02/22/2023 P. Roy Vagelos
Director 		42,500   Derivative/Non-derivative trans. at $270.43 per share. 11,493,275
02/12/2023 Marion McCourt
EVP Commercial 		1,276   Derivative/Non-derivative trans. at $751.78 per share. 959,271
02/07/2023 Marion McCourt
EVP Commercial 		1,000   Disposition at $769.04 per share. 769,040
02/07/2023 Marion McCourt
EVP Commercial 		1,000   Derivative/Non-derivative trans. at $372.46 per share. 372,460
02/06/2023 George Damis Yancopoulos
President and Chief Scientific; Director 		13,189   Disposition at $800.08 per share. 10,552,255
02/06/2023 Robert E. Landry
EVP Finance CFO 		28   Disposition at $797.43 per share. 22,328
02/06/2023 Robert E. Landry
EVP Finance CFO 		18   Disposition at $796.43 per share. 14,335
02/06/2023 Robert E. Landry
EVP Finance CFO 		59   Disposition at $795.41 per share. 46,929
02/06/2023 Robert E. Landry
EVP Finance CFO 		99   Disposition at $794.61 per share. 78,666
02/06/2023 Robert E. Landry
EVP Finance CFO 		2   Disposition at $793.33 per share. 1,586
02/06/2023 Robert E. Landry
EVP Finance CFO 		3   Disposition at $791 per share. 2,373
02/06/2023 Robert E. Landry
EVP Finance CFO 		10   Disposition at $790.41 per share. 7,904
02/06/2023 Robert E. Landry
EVP Finance CFO 		49   Disposition at $789.05 per share. 38,663
02/06/2023 Robert E. Landry
EVP Finance CFO 		99   Disposition at $788.62 per share. 78,073
02/06/2023 Robert E. Landry
EVP Finance CFO 		58   Disposition at $787.47 per share. 45,673
02/06/2023 Robert E. Landry
EVP Finance CFO 		85   Disposition at $786.45 per share. 66,848
02/06/2023 Robert E. Landry
EVP Finance CFO 		78   Disposition at $785.88 per share. 61,298
02/06/2023 Robert E. Landry
EVP Finance CFO 		113   Disposition at $784.27 per share. 88,622
02/06/2023 Robert E. Landry
EVP Finance CFO 		51   Disposition at $783.05 per share. 39,935
02/06/2023 Michael S. Brown
Director 		500   Disposition at $797 per share. 398,500
02/06/2023 Michael S. Brown
Director 		3,071   Disposition at $798 per share. 2,450,658
02/06/2023 Joseph L. Goldstein
Director 		3,613   Disposition at $800 per share. 2,890,400
02/06/2023 Michael S. Brown
Director 		3,071   Derivative/Non-derivative trans. at $520.01 per share. 1,596,950
02/06/2023 Joseph L. Goldstein
Director 		3,613   Derivative/Non-derivative trans. at $482.68 per share. 1,743,922
02/03/2023 Robert E. Landry
EVP Finance CFO 		2,248   Derivative/Non-derivative trans. at $774.29 per share. 1,740,603
02/03/2023 Christopher Robert Fenimore
SVP Controller 		3,286   Derivative/Non-derivative trans. at $774.29 per share. 2,544,316
02/03/2023 Robert E. Landry
EVP Finance CFO 		739   Disposition at $764.5 per share. 564,965
02/03/2023 Bonnie L. Bassler
Director 		1,021   Disposition at $779 per share. 795,359
02/03/2023 Robert E. Landry
EVP Finance CFO 		3,000   Derivative/Non-derivative trans. at $381.92 per share. 1,145,760
02/03/2023 Christopher Robert Fenimore
SVP Controller 		5,000   Derivative/Non-derivative trans. at $270.43 per share. 1,352,150
02/03/2023 Bonnie L. Bassler
Director 		1,021   Derivative/Non-derivative trans. at $380.95 per share. 388,949
02/01/2023 Marion McCourt
EVP Commercial 		1,100   Disposition at $752.19 per share. 827,409
02/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $762.17 per share. 1,524
02/01/2023 Arthur Frederick Ryan
Director 		3   Disposition at $761.58 per share. 2,284
02/01/2023 Arthur Frederick Ryan
Director 		4   Disposition at $760.4 per share. 3,041
02/01/2023 Arthur Frederick Ryan
Director 		4   Disposition at $759.65 per share. 3,038
02/01/2023 Arthur Frederick Ryan
Director 		7   Disposition at $758.58 per share. 5,310
02/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $757.29 per share. 1,514
02/01/2023 Arthur Frederick Ryan
Director 		24   Disposition at $756.77 per share. 18,162
02/01/2023 Arthur Frederick Ryan
Director 		17   Disposition at $755.5 per share. 12,843
02/01/2023 Arthur Frederick Ryan
Director 		17   Disposition at $754.45 per share. 12,825
02/01/2023 Arthur Frederick Ryan
Director 		18   Disposition at $753.54 per share. 13,563
02/01/2023 Arthur Frederick Ryan
Director 		2   Disposition at $752.11 per share. 1,504
02/01/2023 Marion McCourt
EVP Commercial 		1,100   Derivative/Non-derivative trans. at $372.46 per share. 409,706
01/27/2023 Michael S. Brown
Director 		1   Disposition at $747 per share. 747
01/27/2023 Michael S. Brown
Director 		1   Derivative/Non-derivative trans. at $520.01 per share. 520
01/06/2023 Michael S. Brown
Director 		3,070   Disposition at $747.14 per share. 2,293,719
01/06/2023 Michael S. Brown
Director 		3,070   Derivative/Non-derivative trans. at $520.01 per share. 1,596,430
01/04/2023 P. Roy Vagelos
Director 		291   Gift at $0 per share. 0
Copyright 2023 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
22 Purchases
54 Sales
66,166
66,468
Last 6 months
51 Purchases
198 Sales
210,382
198,088
Last 12 months
78 Purchases
353 Sales
460,918
476,174

Officers and Executives

Dr. P. Roy Vagelos
Chairman
Dr. Leonard S. Schleifer
Co-President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos
Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly
Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry
Chief Financial Officer & Executive VP-Finance
Dr. Andrew J. Murphy
Executive Vice President-Research
Mr. Bob McCowan
Chief Information Officer & Senior VP-IT
Dr. Johnathan M. Lancaster
Senior Vice President-Global Medical Affairs
Dr. Neil Stahl
Executive VP-Research & Development
Mr. Nouhad Husseini
Senior VP-Business Development
Mr. Gerald Underwood
Senior Vice President-Technical Operations
Dr. Kerry K. Reinertsen
Senior Vice President-Strategic Alliances
Mr. Daniel P. van Plew
EVP, GM-Industrial Operations & Product Supply
Ms. Beth F. Holly
Senior Vice President
Dr. Alan Shuldiner
Vice President-Translational Genetics
Ms. Marion McCourt
Executive Vice President-Commercial
Dr. Craig B. Thompson
Director
Mr. Mark Volpe
Senior Vice President-Tax
Mr. Christopher Robert Fenimore
Senior VP, Head-Accounting & Controller
Mr. Mark Hudson
Head-Investor Relations
Ms. Sally A. Paull
Senior Vice President-Human Resources
Mr. Joseph J. LaRosa
Secretary, Executive VP & General Counsel
Ms. Maya Bermingham
Senior VP-Public Policy & Government Affairs
Dr. Ned Braunstein
SVP-Regulatory Affairs & Global Patient Safety
Dr. Michael S. Brown
Independent Director
Dr. Joseph L. Goldstein
Independent Director
Mr. George L. Sing
Independent Director
Mr. Arthur Frederick Ryan
Independent Director
Ms. Christine A. Poon
Independent Director
Dr. Marc Tessier-Lavigne
Independent Director
Dr. Bonnie L. Bassler
Independent Director
Dr. Huda Y. Zoghbi
Independent Director
Dr. N. Anthony Coles
Independent Director
Link to MarketWatch's Slice.